Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Sell
42
SXTP Quote, Financials, Valuation and Earnings
Last price:
$5.10
Seasonality move
:
-46.57%
Day range:
$3.34 - $5.19
52-week range:
$1.36 - $24.00
Dividend yield:
0%
P/E ratio:
15.22x
P/S ratio:
2.42x
P/B ratio:
--
Volume:
1.8M
Avg. volume:
6.8M
1-year change:
-72.94%
Market cap:
$6.2M
Revenue:
$681.3K
EPS (TTM):
-$7.32
Analysts' Opinion
-
Consensus Rating60 Degrees Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.40, 60 Degrees Pharmaceuticals, Inc. has an estimated upside of 263.64% from its current price of $4.84.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.80 representing 100% downside risk from its current price of $4.84.
Fair Value
-
According to the consensus of 2 analysts, 60 Degrees Pharmaceuticals, Inc. has 263.64% upside to fair value with a price target of $4.40 per share.
SXTP vs. S&P 500
-
Over the past 5 trading days, 60 Degrees Pharmaceuticals, Inc. has overperformed the S&P 500 by 99.06% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
60 Degrees Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
60 Degrees Pharmaceuticals, Inc. has grown year-over-year revenues for 7 quarters straight. In the most recent quarter 60 Degrees Pharmaceuticals, Inc. reported revenues of $528.6K.
Earnings Growth
-
60 Degrees Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter 60 Degrees Pharmaceuticals, Inc. reported earnings per share of -$0.66.
Enterprise value:
11.8M
EV / Invested capital:
--
Price / LTM sales:
2.42x
EV / EBIT:
27.43x
EV / Revenue:
8.68x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-1.71x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
21.64x
Gross Profit (TTM):
$575.1K
Return On Assets:
-132.46%
Net Income Margin (TTM):
-588.79%
Return On Equity:
-193.16%
Return On Invested Capital:
-186.16%
Operating Margin:
-439.94%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $529.3K | $451.8K | $1.4M | $148.1K | $528.6K | |
| Gross Profit | $108.7K | $38.9K | $575.1K | $36.4K | -$9.1K | |
| Operating Income | -$3.5M | -$9.5M | -$7.9M | -$2.1M | -$2.3M | |
| EBITDA | -$3.4M | -$9.5M | -$7.8M | -$2.1M | -$2.3M | |
| Diluted EPS | -$63.41 | -$82.40 | -$24.61 | -$0.93 | -$2.66 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $8.9M | $6.9M | $6.3M | |
| Total Assets | -- | -- | $9.2M | $7.4M | $6.7M | |
| Current Liabilities | -- | -- | $2.5M | $1.3M | $2.2M | |
| Total Liabilities | -- | -- | $2.6M | $1.5M | $2.3M | |
| Total Equity | -- | -- | $6.5M | $6M | $4.3M | |
| Total Debt | -- | -- | $161.4K | $156.7K | $153.8K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$4.5M | -$4.1M | -$6.8M | -$1.7M | -$2.1M | |
| Cash From Investing | -$108K | -$2M | $1.6M | -$1.7M | -$25.5K | |
| Cash From Financing | $6.4M | $7.1M | $6M | $5.2M | $4.3M | |
| Free Cash Flow | -$4.7M | -$4.3M | -$6.9M | -$1.7M | -$2.1M | |
SXTP
Sector
Market Cap
$6.2M
$25.9M
Price % of 52-Week High
20.17%
51.6%
Dividend Yield
0%
0%
Shareholder Yield
-275.12%
-1.66%
1-Year Price Total Return
-72.94%
-18.99%
Beta (5-Year)
--
0.485
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.08
200-day SMA
Sell
Level
$6.51
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$2.52
Relative Strength Index (RSI14)
Buy
Level
68.66
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-52.0661
50-day SMA
Buy
Level
$3.29
MACD (12, 26)
Buy
Level
0.67
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.1156)
Sell
CA Score
(Annual)
Level (-5.9875)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (10.8579)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.
Stock Forecast FAQ
In the current month, SXTP has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SXTP average analyst price target in the past 3 months is $4.40.
-
Where Will 60 Degrees Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that 60 Degrees Pharmaceuticals, Inc. share price will rise to $4.40 per share over the next 12 months.
-
What Do Analysts Say About 60 Degrees Pharmaceuticals, Inc.?
Analysts are divided on their view about 60 Degrees Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that 60 Degrees Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $2.80.
-
What Is 60 Degrees Pharmaceuticals, Inc.'s Price Target?
The price target for 60 Degrees Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $4.40 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SXTP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for 60 Degrees Pharmaceuticals, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SXTP?
You can purchase shares of 60 Degrees Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase 60 Degrees Pharmaceuticals, Inc. shares.
-
What Is The 60 Degrees Pharmaceuticals, Inc. Share Price Today?
60 Degrees Pharmaceuticals, Inc. was last trading at $5.10 per share. This represents the most recent stock quote for 60 Degrees Pharmaceuticals, Inc.. Yesterday, 60 Degrees Pharmaceuticals, Inc. closed at $4.84 per share.
-
How To Buy 60 Degrees Pharmaceuticals, Inc. Stock Online?
In order to purchase 60 Degrees Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SXTP Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SXTP
Sector
P/E ratio
15.22x
23.82x
PEG ratio
0.00x
-0.01x
P/B ratio
--
1.83x
Price / LTM sales
2.42x
1.56x
Growth Metrics
SXTP
Sector
Revenue growth
256.87%
4.18%
Earnings growth
28.52%
9.66%
Revenue (5-year growth)
--
6.28%
Earnings forecast
-$2.00
-$0.18
Profitability
SXTP
Sector
Profitability FY 2024
$296.6K
$3.1M
Return on invested capital
-186.16%
-32.89%
Return on assets
-132.46%
-29.56%
Return on equity
-193.16%
-38.66%
Earnings Date
Last Earnings Date
Aug
12
Next Earnings Date
Jan
27
Estimated Next Earnings Date
Apr
28
Balance Sheet
SXTP
Sector
Total cash
$4.1M
$25.2M
Short term investments
--
$25.1M
Total assets
$5.8M
$73M
Long term debt
$153.8K
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
73
BNAI alert for Jan 27
Brand Engagement Network, Inc. [BNAI] is up 279.19% over the past day.
Buy
71
GLSI alert for Jan 27
Greenwich LifeSciences, Inc. [GLSI] is up 19.36% over the past day.
Sell
48
RVMD alert for Jan 27
Revolution Medicines, Inc. [RVMD] is down 16.89% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
